{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-149623","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.047377+00:00","generated_at":"2026-05-15T06:45:39.286901+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement","bullets":["Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.","Josh Muntner named CFO effective April 6, 2026; base salary $475K, 40% bonus; granted options to buy 486,650 shares at $1.58.","Ajay Aggarwal appointed COO effective April 27, 2026; base salary $490K, 40% bonus; expects 400,000 stock options.","Muntner has 25+ years biopharma finance experience, previously CFO at Imvax and Mesoblast, raised over $300M combined.","Dr. Aggarwal brings 15+ years pharma experience, most recently SVP Clinical Development at Aclaris Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-149623","json":"https://secwatch.observer/filing/0001193125-26-149623.json","markdown":"https://secwatch.observer/filing/0001193125-26-149623.md","text":"https://secwatch.observer/filing/0001193125-26-149623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/0001193125-26-149623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/crdf-20260406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:45:39.286901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}